Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth

Epidermal growth factor receptor (EGFR) activation plays a pivotal role in EGFR-driven non-small cell lung cancer (NSCLC) and is considered as a key target of molecular targeted therapy. EGFR tyrosine kinase inhibitors (TKIs) have been canonically used in NSCLC treatment. However, prevalent innate a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Nan, Wang, Chen-Ran, Liu, Ming-Qun, Li, Ying-Jie, Chen, Wei-Min, Li, Zheng-Qiu, Qi, Qi, Lu, Jin-Jian, Fan, Chun-Lin, Chen, Min-Feng, Qi, Ming, Li, Xiao-Bo, Hong, Jian, Zhang, Dong-Mei, Ye, Wen-Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544691/
https://www.ncbi.nlm.nih.gov/pubmed/33033232
http://dx.doi.org/10.1038/s41392-020-00251-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544691/
https://www.ncbi.nlm.nih.gov/pubmed/33033232
http://dx.doi.org/10.1038/s41392-020-00251-2

Ejemplares similares